<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5256">
  <stage>Registered</stage>
  <submitdate>24/04/2015</submitdate>
  <approvaldate>24/04/2015</approvaldate>
  <nctid>NCT02429895</nctid>
  <trial_identification>
    <studytitle>A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-005527-27</secondaryid>
    <secondaryid>M14-198</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriatic Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-122

Experimental: All subjects (open-label extension) - All subjects will start treatment with ABT-122


Treatment: drugs: ABT-122
Injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>American College of Rheumatology (ACR) 20 response rate by visit - ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>American College of Rheumatology (ACR) 50 response rate by visit - ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>American College of Rheumatology (ACR) 70 response rate by visit - ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in American College of Rheumatology (ACR) the individual component by visit - ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Disease Activity Score DAS28 [hsCRP] by visit - Determine by disease activity score using 28 joint counts (DAS28) and high-sensitivity C-reactive protein (hsCRP) lab test.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Psoriatic Disease Activity Score (PASDAS) by visit - PASDAS determined by tender or swollen joint counts, patient reported outcome and hsCRP lab test.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Psoriasis Area and Severity Index (PASI) by visit - Determined by scores for the amount and severity of a patient's psoriasis.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Psoriasis Target Lesion Score by visit - Determined by plaque erythema, plaque scaling and plaque thickness scores.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Dactylitis Assessment by visit - Determined by presence of dactylitis, swelling, and tenderness in each digit of both hands and both feet.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Enthesitis Sites Comprising the Total Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index by visit - Determined by the presence and severity of enthesitis.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in Self-Assessment of Psoriasis Symptoms (SAPS) by visit - Determined by scores given by patients regarding the severity of their psoriatic symptoms.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in skin biopsy/biomarkers - Optional samples to assess changes related on disease activity/prognosis of psoriatic arthritis (PsA), autoimmunity/inflammation, and/or response to anti-PsA medications.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in the quality of life, function and work as measured by the Short-Form Health Survey Version 2.0 (SF36v2) by visit - Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in the quality of life, function and work as measured by Bath AS Disease Activity Index (BASDAI) by visit - Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in the quality of life, function and work as measured by the Fatigue Numeric Rating Scale by visit - Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in the quality of life, function and work as measured by the Sleep Quality Scale by visit - Quality of life are self reported measures to assess the physical function of the patient and how their activities are impacted by their disease.</outcome>
      <timepoint>From Week 0 to Week 24</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subjects who have completed preceding Study M14-197 (ABT-122) RCT study and have not
             developed any discontinuation criteria of Study M14-197.

          2. If female, subject must meet one of the following criteria:

               -  Postmenopausal (defined as no menses for at least 1 year).

               -  Surgically sterile (bilateral oophorectomy or hysterectomy)

             If subject does not meet one of the above two categories, subject must use one of the
             following methods of birth control, from the time of the first dose of study drug
             until 150 days after the last dose of study drug:

               -  Combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation started at least 2 months prior to the first dose of
                  study drug: oral, intravaginal or transdermal

               -  Progestogen-only hormonal contraception associated with inhibition of ovulation
                  started at least two months prior to randomization: oral, injectable, or
                  implantable

               -  Intrauterine device (IUD)

               -  Intrauterine hormone-releasing system (IUS)

               -  Bilateral tubal occlusion/ligation

               -  Be with a vasectomized partner (procedure at least 6 months earlier, the
                  vasectomized male partner should be your sole partner)

               -  Sexual abstinence (refraining from heterosexual intercourse during the entire
                  study period)

          3. If male, subject must be surgically sterile (have had a vasectomy more than 6 months
             prior to Screening) or must be practicing at least 1 of the following methods of birth
             control from the time of the first dose of study drug until 150 days post last dose of
             study drug:

               -  Subject using condom and female partner(s) using an intrauterine device (IUD);

               -  Subject using condom and female partner(s) using hormonal contraceptives (oral,
                  vaginal, parenteral or transdermal);

               -  Subject using condom and female partner(s) using double-barrier method
                  (contraceptive sponge; diaphragm or vaginal ring with spermicidal jellies,
                  creams, or spermicide);

               -  Total abstinence from sexual intercourse as the preferred lifestyle of the
                  subject; periodic abstinence is not acceptable.

               -  Subject must also agree to not donate sperm starting on the first day of study
                  drug administration until 150 days after the last dose of study drug.

          4. Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any study-specific procedures.

          5. Subject is judged to be in good health as determined by the Investigator.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pregnant or breastfeeding or plans to become pregnant during study participation.

          2. Ongoing infections at Day 1 (Week 0) that have NOT been successfully treated within 14
             days.

          3. Anticipated requirement or receipt of any live vaccine during study participation
             including up to 120 days after the last dose of study drug.

          4. Current enrollment in another investigational study; with the exception of Study
             M14-197, which is required.

          5. Consideration by the Investigator, for any reason, that the subject is an unsuitable
             candidate to continue to receive ABT-122.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>168</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 138922 - Woolloongabba</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Plovdiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Luebeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Adazi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Valmiera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Newtown, Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Elblag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Oswiecim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Stalowa Wola</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Torun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucuresti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targu-Mures, Jud. Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santiago de Compostela</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic
      Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled
      Trial (RCT).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02429895</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Heikki T Mansikka, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>